公开(公告)号：US20130224108A1

公开(公告)日：2013-08-29

申请号：US13021442

申请日：2011-02-04

申请人： Luis A.G. Da Cruz ,  Elizabeth Jane Franzmann

发明人： Luis A.G. Da Cruz ,  Elizabeth Jane Franzmann

IPC分类号： C07K16/28

CPC分类号： C07K16/2884 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof.

公开(公告)号：US20090022722A1

公开(公告)日：2009-01-22

申请号：US12220362

申请日：2008-07-23

申请人： David S.F. Young ,  Helen P. Findlay ,  Susan E. Hahn ,  Lisa M. Cechetto ,  Luis A.G. da Cruz

发明人： David S.F. Young ,  Helen P. Findlay ,  Susan E. Hahn ,  Lisa M. Cechetto ,  Luis A.G. da Cruz

IPC分类号： A61K39/395 ,  C07K16/00 ,  G01N33/574

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/24 ,  G01N33/57492 ,  G01N2333/70596

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。